Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 23;119(36):e2120680119. doi: 10.1073/pnas.2120680119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 the Author(s). Published by PNAS.

This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

PMC Copyright notice

Fig. 2. — scRNA-seq analysis of lincRNA expression during COVID-19. (A) Patient PBMC analysis strategy. (B) Validation of immune marker induction in COVID-19 cohort PBMCs (qRT-PCR, control-patient 1 set as reference). (C) UMAP-plot with color-coded cell populations identified in merged scRNA-seq data. (D) HLA mRNA expression profile (scRNA-seq, monocytes highlighted). (E) FACS validation of immature neutrophil (CD15⁺⁺/CD24⁺⁺) appearance and reduction of classic monocytes (CD14⁺⁺/CD16^dim) in COVID-19 (color-coded according to A). (F) Volcano plot (Upper) and Reactome pathway (Lower) analysis of classic monocyte response during COVID-19 (scRNA-seq). (G) LincRNA profiles in control and COVID-19 patients (scRNA-seq). (H) PIRAT and LUCAT1 expression in classic (Class) and nonclassic (CD16) monocytes, myeloid dendritic cells (mDC), and plasmacytoid DCs (pDC) (qRT-PCR). (I) Same as B, but for PIRAT and LUCAT1. (B, E, and I) Two-tailed Student’s t test. (H) One-way ANOVA, three independent experiments. *P ≤ 0.05; **P ≤ 0.01.